Wiley Blackwell

SHERPA: Unknown

People

  1. Kumar
    Kumar
  2. Moskowitz
    Moskowitz
  3. Zelenetz
    Zelenetz
  4. Hamlin
    Hamlin
  5. Noy
    Noy
  6. Palomba
    Palomba
  7. Horwitz
    Horwitz
  8. Seshan
    Seshan
  9. Yahalom
    Yahalom
  10. Dogan
    Dogan

Groups

  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Executive Committee, Center for Hematologic Malignancies (25)
  4. Hematologic Malignancies, Division of (25)
  5. Lymphoma (25)
  6. Hematology-Oncology Fellows (13)
  7. Survivorship Research (11)
  8. Epidemiology and Biostatistics (10)
  9. Biostatistics Service (9)
  10. Population Sciences Research Program (8)
Search Within
  1. "Anas Younes"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (5)
  3. Conference Paper (1)
  4. Review (1)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Executive Committee, Center for Hematologic Malignancies (25)
  4. Hematologic Malignancies, Division of (25)
  5. Lymphoma (25)
  6. Hematology-Oncology Fellows (13)

More Groups

People
  1. Anas Younes (25)
  2. Connie Batlevi (12)
  3. Matthew Matasar (11)
  4. Alison Moskowitz (10)
  5. Andrew Zelenetz (10)
  6. Anita Kumar (10)

More People

Years
  1. 2023 (1)
  2. 2021 (1)
  3. 2019 (11)
  4. 2018 (1)
  5. 2017 (8)
  6. 2015 (1)

More Years

Publications
  1. Hematological Oncology (22)
  2. Cancer (2)
  3. eJHaem (1)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
    Journal Article

    Kostakoglu, L.; Martelli, M.; Sehn, L. H.; Davies, A.; Trneny, M.; Herold, M.; Vitolo, U.; Hiddemann, W.; Trotman, J.; Knapp, A.; more...
    eJHaem (2023)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Dose finding study to assess safety, PK and efficacy of fimepinostat (CUDC‐907) with venetoclax or rituximab plus bendamustine in patients with relapsed/refractory lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; Kelly, K.; Landsburg, D. J.; Patel, K.; Phillips, T.; Smith, S.; Westin, J.; Ma, A. W.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical significance and outcomes in patients with diffuse large B‐cell lymphoma (DLBCL) harboring extra copies [EC] and/or translocations [TL] of MYC, BCL2, and BCL6
    Meeting Abstract

    Sermer, D.; Bobillo, S.; Seshan, V.; Dogan, A.; Younes, A.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis in the PH 3 ECHELON‐1 study: Worse outcome with ABVD in patients with elevated baseline levels of SCD30 and TARC
    Meeting Abstract

    Radford, J.; Connors, J. M.; Younes, A.; Gallamini, A.; Ansell, S. M.; Kim, W. S.; Cheong, J.; Flinn, I.; Kalakonda, N.; Kaminski, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • EZH2 gain‐of‐function mutations are not associated with more favorable prognosis in relapsed/refractory follicular lymphoma (FL): A preliminary analysis on 590 patients
    Meeting Abstract

    Okosun, J.; Bödör, C.; Batlevi, C.; Nagy, N.; Michot, J.; Schneider, T.; Alizadeh, H.; Simon, Z.; Vose, J.; Younes, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save